News | February 23, 2022
GSK introduces Haleon to the world
Haleon will have a portfolio of category-leading brands including Sensodyne, Voltaren, Panadol and Centrum
Haleon will have a portfolio of category-leading brands including Sensodyne, Voltaren, Panadol and Centrum
Ligand expects 2022 royalties of $55 million to $60 million, material sales of $40 million to $50 million, and contract revenue of $52 million to $62 million.
The three prequalified products are manufactured by the originator company, Roche, but the listings should pave the way for more companies coming forward to seek WHO prequalification
Dr. Reddy’s included in S&P Global’s Sustainability Yearbook for the 2nd year and Bloomberg Gender-Equality Index for the 5th year in a row
It would be the first protein-based alternative available in Israel
Biocon has reported consolidated financial results for the period ended December 31, 2021
Novavax' vaccine has received authorizations of the vaccine in over 170 countries
All the recommendations have been sent to the Drugs Controller General of India (DCGI) for final approval.
SAGE recommends additional third dose of the vaccine administered to immunocompromised persons
First Emergency Use Listing granted by WHO for a protein-based Covid-19 vaccine
Subscribe To Our Newsletter & Stay Updated
